Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

Innovate UK is to invest up to £30 million to establish a network of 3 advanced therapies treatment centres in the UK

Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery

Evotec has made a € 15 M investment to take a minority stake in Exscientia.

Read the rest of entry »

Arecor Announces License Agreement With Global Pharmaceutical Company

Global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.

Read the rest of entry »

DNAe Previews its Semiconductor Genomic Analysis Test to Address the Challenge of Sepsis

LiDia™ Bloodstream Infection (BSI) Test showcased at an Imperial College/Royal Institution Technology vs Infectious Diseases Summit, London

Read the rest of entry »

Cell-line Derived Controls for Diagnostic Assay Development

AMSBIO announce the addition of mutation cell line Formalin-Fixed Paraffin-Embedded (FFPE) samples and isolated genomic DNA (gDNA) controls to its extensive range of cell line reference standards.

Read the rest of entry »

Wickham Laboratories Announces Successful MHRA GMP Inspection

Wickham Laboratories reports a successful completion of the MHRA audit process and the subsequent renewal of GMP accreditation.

Read the rest of entry »

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Read the rest of entry »

The CLASP Healthcare call has £2m to fund a small number of projects ranging from short feasibility studies to larger developmental projects

The proposals led by eligible STFC scientists will provide solutions to address the healthcare grand challenges using STFC science, technologies and skills. User engagement is encouraged.  

Read the rest of entry »

Replimune Appoints Howard L. Kaufman, M.D., FACS as Chief Medical Officer

Replimune Group Inc. announced today a key addition to its senior leadership team as it progresses its Immulytic™ oncolytic immunotherapy platform rapidly towards clinical trials.

Read the rest of entry »

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs

Biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.